Cuộc họp báo cáo kết quả kinh doanh Q2 2026 của VolitionRx (VNRX): Chi phí giảm khi danh mục phát triển Nu.Q đạt tiến triển
Doanh thu Quý 2/2026 của VolitionRx duy trì ở mức 0,4 triệu USD trong khi chi phí giảm 32%. VNRX đã nhấn mạnh về Nu.Q NETs, chính sách hoàn trả chi phí xét nghiệm ung thư phổi và các cột mốc quan trọng trong mảng sản phẩm dành cho mèo.
VolitionRx Limited is a multi-national company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.